Newsroom

News from and about Adial as well as important reporting about the field of addiction.

Featured Story

Adial Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds

Under the collaboration agreement, Dr. Ernst and his team will initially test Purnovate’s adenosine compounds in non-clinical models of IBD with the goal of further validating the potential of Purnovate’s compounds as a treatment for IBD. Dr. Ernst stated, “Based on experience, I am keen to see whether these adenosine analogs can effectively address the historical challenges of solubility and biodistribution. My team looks forward to evaluating the compounds for their potential therapeutic benefit to patients suffering from inflammatory bowel disease and other inflammatory conditions.”

Learn More

Press Releases

Past News

Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH

Continue Reading

Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Continue Reading

Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders

Continue Reading

Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th

Continue Reading

Events

Past Events

YouTube Channel (AdialPharma)

Subscribe to Channel

About the growing AUD market and Adial's targeted potential treatment

Watch Now

NBC29: UVA Researchers & Adial looking into using Purnovate in Burn Wound Care

Watch Now

CEO Bill Stilley talks about AD04 on CBS46 Atlanta

Watch Now

Newsy Morning Rush with Bill Stilley discussing AUD & AD04

Watch Now